Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with a US-based pharmaceutical company, extending the contract end date and disclosure postponement deadline from December 31, 2024, to December 31, 2026, upon the customer’s request.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) Single Sales and Supply Contract
- Original Filing Date: December 3, 2019
- Reason for Correction: Extension of contract period upon customer request
- Key Correction Items:
- Contract End Date: (Before) December 31, 2024 ➔ (After) December 31, 2026
- Postponement Deadline: (Before) December 31, 2024 ➔ (After) December 31, 2026
- Expected Counterparty Disclosure Date: (Before) After December 31, 2024 ➔ (After) After December 31, 2026
- Contract Details (As Revised in Filing):
- Contract Classification & Title: Other Sales/Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Amount: KRW 68,697,863,520 (USD 58,198,800, applied exchange rate KRW 1,180.40 per USD on initial disclosure date Dec 3, 2019)
- Recent Annual Revenue: KRW 535,805,801,067 (Based on FY2018 revenue at initial disclosure)
- Contract Amount to Revenue Ratio: 12.82%
- Counterparty: Pharmaceutical company based in the US
- Contract Period: December 3, 2019 – December 31, 2026
- Contract Date: December 3, 2019
- Disclosure Postponement Details:
- Reason for Postponement: Business confidentiality
- Postponement Deadline: December 31, 2026
- Other Important Details:
- The contract amount reflects an increase of USD 11,440,800 from the previously guaranteed minimum amount (USD 46,758,000) to USD 58,198,800.
- The contract end date is subject to change upon mutual agreement.
- Related Disclosures:
- December 3, 2019: Single Sales and Supply Contract
- November 10, 2020: Single Sales and Supply Contract
- December 30, 2022: Single Sales and Supply Contract
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Extension and Postponement Schedule
This correction disclosure provides notice that the contract period end date and confidentiality postponement deadline for the pharmaceutical contract manufacturing agreement with a US-based company have been extended to December 31, 2026, at the client’s request.
Tracking contract performance progress and subsequent official disclosures regarding counterparty details upon the updated postponement deadline (December 31, 2026) is essential.
Relevant developments can be verified in subsequent official disclosures and periodic filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
